Highlights & Insights

A new analysis of the pipeline of novel therapies for prostate cancer, such as PARP inhibitors, PSMA-targeted radioligands and AKT inhibitors - and their potential market impact.

Novavax’s quest to scale up operations underscores how difficult it can be to launch a vaccine ― even with the formula and technology in hand. So what happened?

Among the 13 FDA approvals during the second quarter of 2021, one has undoubtedly been the biggest talking point - Biogen’s Alzheimer disease drug Aduhelm (aducanumab).

Nearly 90 percent of newly launched medicines are available in the United States.

Jointly issued by the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI).

In the last five years, 18 states have passed legislation requiring prescription drug manufacturers to disclose certain price information for their drugs.

With the U.S. FDA endorsing its 29th novel drug on June 30, the drug industry was slightly ahead of last year’s pace.

If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?

Another July, another round of drug price hikes in America.

The Trump administration’s effort to require hospitals to disclose their rates in a “consumer-friendly format” was praised by patients and employers who worried the lack of transparency kept prices high.

“Extreme” drug price increases for antiparasitic medication were associated with increased total outpatient treatment costs, or TOCs.

This brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those estimates or where there is uncertainty in them.